Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, 2022. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘ Company Events ’ sub-page of the Company’s Investor Relations website and embedded into the live webcast.
Conference Call and Webcast Information - Live
Date: | Thursday, February 10, 2022, at 4:30 p.m. Eastern Time | |||
Dial in: | 844-887-9402 | |||
| 412-317-6798 (international) | |||
Hosts: | Dr. James A. Hayward, chairman, president, and CEO | |||
| Beth Jantzen, chief financial officer | |||
Webcast: | https://services.choruscall.com/mediaframe/webcast.html?webcastid=fG5RNOCf |
Conference Call and Webcast Information - Replay
A telephonic replay of the conference call will be available for one week beginning one hour after the end of the live conference call.
Dial in: | 877-344-7529 | ||
| 412-317-0088 (international) | ||
| Access Code: 2723913 | ||
Webcast: | https://services.choruscall.com/mediaframe/webcast.html?webcastid=fG5RNOCf | ||
Availability: | Telephonic replay: until Thursday, February 17, 2022; webcast replay: 1 year |
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a high-throughput turnkey solution for population-scale COVID-19 testing. safeCircle is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies that increase testing efficiencies and provide for rapid turn-around-times.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn . Join our mailing list .
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005647/en/
Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN